Electra is building a pipeline of novel therapies targeting SIRP, a family of cell surface receptors on various immune cell types. The company is taking a first-in-class approach to engage SIRP beyond the current drug development efforts in cancer, by targeting specific SIRP proteins to deplete targeted pathological immune cells.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/16/22 | $84,000,000 | Series B |
Cormorant Asset Management Cowen Healthcare Investments New Leaf Venture Partners OrbiMed Advisors  RA Capital Management Redmile Group Westlake Village BioPartners | undisclosed |
| 10/27/25 | $183,000,000 | Series C |
Blue Owl EQT Life Sciences Mubadala Capital Nextech Ventures OrbiMed Advisors RA Capital Management Sanofi | undisclosed |
